Trends in molecular medicine
March 1, 2023
Ji-Woon Kim, Kanzo Suzuki, Ege T Kavalali et al.
Acute (R,S)-ketamine (ketamine) administration produces rapid antidepressant effects that in some patients can be sustained for several days to more than week. Ketamine blocks NMDA receptors to elicit specific downstream signaling that induces a novel form of synaptic plasticity in the hippocampus that has been linked to the rapid antidepressant action. These signaling events lead to subsequent...
Journal of Psychiatric Research
March 1, 2023
Mu-Hong Chen, T. Su, Li-Fen Chen et al.
BACKGROUND Whether cortical excitation and inhibition functions differ between patients with treatment-resistant depression (TRD) and strong suicidal ideation (SI) and healthy subjects and whether 0.5 mg/kg ketamine infusion can modulate cortical excitation and inhibition functions among patients with TRD-SI remain unclear. METHODS A total of 29 patients with TRD-SI and 35 age- and sex-matched...
March 1, 2023
Cecilia Cannarozzo, Anna Rubiolo, Plínio Casarotto et al.
Ketamine has been described as a fast‐acting antidepressant, exerting effects in depressed patients and in preclinical models with a rapid onset of action. The typical antidepressant fluoxetine is known to induce plasticity in the adult rodent visual cortex, as assessed by a shift in ocular dominance, a classical model of brain plasticity, and a similar effect has been described for ketamine...
European Psychiatry
March 1, 2023
Erhan Kavakbasi, Bernhard T Baune
IntroductionNMDA-Receptor antagonists have rapid antidepressant and antisuicidal properties. However, the antidepressant effect is short lasting raising the question of best maintenance strategy, which is unanswered so far. Invasive vagus nerve stimulation (VNS) as a treatment option for refractory and chronic major depression was shown to reduce the need of maintenance treatment sessions in...
European Psychiatry
March 1, 2023
A. T. Guterman, K. Feffer, A. Z. Gershi
IntroductionDepressive disorders are among the leading causes of disability. The lifetime risk for developing clinically significant depression is estimated around 15%. Multiple studies have found female-male ratio of 2:1 across nations and cultures. The reason for this marked difference is still not clear, although several theories addressing social, biological, and environmental contributors...
Medicine
March 1, 2023
Wei Wang, Bin Ling, Qian Chen et al.
Background: To evaluate the effect of pre-administration of esketamine intraoperatively on the occurrence of postpartum depression after cesarean section under combined spinal-epidural anesthesia. Methods: A total of 120 women aged 24 to 36 years undergoing cesarean section by spinal-epidural anesthesia with American Society of Anesthesiologists physical status II were enrolled. According to...
Experimental and therapeutic medicine
March 2023
Octavian Vasiliu
Treatment-resistant depression (TRD) is a challenge for psychiatrists, even after more than seven decades since the first antidepressants were used in clinical practice. Non-monoaminergic-based drugs with antidepressant properties have been developed, but to date, only esketamine and brexanolone have been approved for TRD and postpartum depression, respectively. A narrative review on the...
PubMed Central
March 1, 2023
INTRODUCTION: Treatment resistant depression (TRD) is estimated to affect 10–30% of patients with major depressive disorder (Al‑Harbi et al. Patient Prefer Adherence 2012; 6 369–88). Esketamine nasal spray (NS), in combination with a selective serotonin reuptake inhibitor (SSRI) or serotonin norepinephrine reuptake inhibitor (SNRI), increases remission and response rates in patients with TRD...
Journal of Affective Disorders
March 1, 2023
Debora de A. Simoes Moreira, Luís Eduardo Gauer, Guilherme Teixeira et al.
25 citations
Background: ECT is considered the fastest and most effective treatment for TRD. Ketamine seems to be an attractive alternative due to its rapid-onset antidepressant effects and impact on suicidal thoughts. This study aimed to compare efficacy and tolerability of ECT and ketamine for different depression outcomes (PROSPERO/CRD42022349220). Methods: We searched MEDLINE, Web of Science, Embase,...
European Psychiatry
March 1, 2023
V. W. L. Tsang, R. Moyer, P. Kryskow et al.
2 citations
IntroductionHealthcare practitioners (HCPs) are facing a mental health crisis. Group therapies have long been used to treat symptoms associated with PTSD, anxiety and/or depression, however no studies have investigated the role of implementing group therapy with and without ketamine-assisted therapies (KaT).ObjectivesThe current study investigated the effects of the Roots to Thrive (RTT) group...
European Psychiatry
March 1, 2023
V. W. L. Tsang, Brendan Tao, Shannon Dames et al.
1 citation
IntroductionKetamine has been increasingly used to treat mental health conditions yet there is a lack of safety data on intramuscular (IM) and sublingual (SL) dosing in a community setting. The Roots to Thrive Ketamine assisted Therapy (RTT-KaT) program is a 12-week program with 12 Community of Practice (CoP) group therapy sessions and three ketamine sessions.ObjectivesTo provide preliminary...
Journal of Affective Disorders
February 28, 2023
Ming Jiang, Qianqian Li, Mingjie Mao et al.
Background: Patients with missed miscarriages are usually accompanied by varying degrees of depression, which is closely related to the patient's prognosis. We investigated whether Esketamine could alleviate postoperative depression symptoms in patients with missed miscarriages who underwent painless curettage. Methods: This study was a randomized, parallel-controlled, double-blind,...
February 28, 2023
Ketamine therapies can offer rapid relief of depression and an antisuicidal effect, making them of particular interest for adolescents with treatment-resistant depression. In 1 randomized, double-blind study of adolescents with severe major depression, ketamine had a strong effect size for reducing depressive symptoms 24 hours after infusion. Currently, there is minimal investigation and few...
Journal of Clinical Psychopharmacology
February 24, 2023
Brandi Quintanilla, Gustavo C Medeiros, D. Greenstein et al.
Abstract Background Preclinical evidence indicates that the κ-opioid receptor (KOR)/dynorphin pathway is implicated in depressive-like behaviors. Ketamine is believed to partly exert its antidepressant effects by modulating the opioid system. This post hoc study examined the following research questions: (1) at baseline, were there differences in KOR or dynorphin plasma levels between...
bioRxiv Preprint Server
February 21, 2023
Naomi R. Driesen, Peter Herman, Margaret A. Rowland et al.
5 citations
preprint
Working memory (WM) is a crucial resource for temporary memory storage and the guiding of ongoing behavior. N-methyl-D-aspartate glutamate receptors (NMDARs) are thought to support the neural underpinnings of WM. Ketamine is an NMDAR antagonist that has cognitive and behavioral effects at subanesthetic doses. To shed light on subanesthetic ketamine effects on brain function, we employed a...
Neuropharmacology
February 20, 2023
Ege Kingir, Cem Sevinc, Gunes Unal
Acute injections of ketamine lead to rapid but transient antidepressant effects. Chronic oral treatment at low doses, a promising non-invasive alternative, may prolong this therapeutic effect. Here, we examine the antidepressant effects of chronic oral ketamine in rats under chronic unpredictable mild stress (CUMS), and reveal their neuronal correlates. Male Wistar rats were divided into...
Substance Abuse Treatment, Prevention, and Policy
February 17, 2023
Florence Jaguga, Philip Kirwa, Benson N. Gakinya et al.
3 citations
BACKGROUND: Alcohol use disorder is prevalent globally and in Kenya, and is associated with significant health and socio-economic consequences. Despite this, available pharmacological treatment options are limited. Recent evidence indicates that intravenous (IV) ketamine can be beneficial for the treatment of alcohol use disorder, but is yet to be approved for this indication. Further, little...
Translational Psychiatry
February 16, 2023
Lena Vera Danyeli, Zümrüt Duygu Sen, Lejla Colic et al.
15 citations
Abstract Ketamine shows rapid antidepressant effects peaking 24 h after administration. The antidepressant effects may occur through changes in glutamatergic metabolite levels and resting-state functional connectivity (rsFC) within the default mode network (DMN). A multistage drug effect of ketamine has been suggested, inducing acute effects on dysfunctional network configuration and delayed...
Addiction
February 15, 2023
Zhen-Xiang Gao, T. Winhusen, Maria P Gorenflo et al.
Background and aims: Cocaine use disorder (CUD) is a significant public health issue for which there is no Food and Drug Administration (FDA) approved medication. Drug repurposing looks for new cost-effective uses of approved drugs. This study presents an integrated strategy to identify repurposed FDA-approved drugs for CUD treatment. Design: Our drug repurposing strategy combines artificial...
Frontiers in Cellular Neuroscience
February 15, 2023
Cui-Hong Zhou, Xinxin Zhao, Xinxu Ma et al.
Introduction: Compelling evidence indicates that a single sub-anesthetic dose of (S)-ketamine elicits rapid and robust antidepressant effects. However, the underlying mechanisms behind the antidepressant effects of (S)-ketamine remain unclear. Methods: Here, using a chronic variable stress (CVS) model in mice, we analyzed changes inthe lipid compositions of the hippocampus and prefrontal cortex...